Business Context and Reporting Period
HeartCore Enterprises, Inc. filed a Form 8-K dated November 9, 2022, with the report signed and filed on November 23, 2022. The filing reports consulting-related agreements and equity compensation arrangements involving SYLA Technologies Co., Ltd. and SBC Medical Group, Inc. HeartCore provides support services to Japanese companies pursuing U.S. listings.
Key Financial and Operating Information
| Item | Filing disclosure |
|---|---|
| Revenue or fees | No historical revenue, profit, cash flow, margin, debt, or liquidity data are provided. Under the SBC Medical agreement, HeartCore is to receive aggregate cash fees of $900,000 over six months: $400,000 at signing, $250,000 after three months, and $250,000 after six months. |
| Equity compensation | HeartCore received a fully vested warrant for shares equal initially to 2.7% of SBC Medical’s fully diluted share capital, exercisable at $0.01 per share after an applicable IPO, SPAC transaction, or other qualifying transaction. |
| SYLA rights | SYLA allotted 5,771 stock acquisition rights to HeartCore for consulting services. The exercise price is $0.01 per share, and the underlying shares are intended to represent 2% of SYLA’s fully diluted shares, subject to adjustment. |
| Debt and liquidity | The filing does not provide debt balances, cash balances, liquidity measures, or financing information. |
Material Changes Versus the Prior Comparable Period
- HeartCore entered into a new six-month consulting agreement with SBC Medical on November 18, 2022, providing for $900,000 of cash fees and a warrant representing an initial 2.7% fully diluted equity interest.
- The company received 5,771 SYLA stock acquisition rights under a November 9, 2022 allotment agreement in exchange for consulting services.
- The previously issued SYLA warrant for 37,500 shares was terminated under Amendment No. 2 to the SYLA Consulting Agreement. In exchange, SYLA agreed to pay the $150,000 second payment, contingent on SYLA completing a listing on Nasdaq Capital Market or NYSE American.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that it expects to generate an aggregate initial fee of $900,000 from the SBC Medical engagement and highlighted the related 2.7% warrant.
- The SBC Medical agreement does not guarantee that SBC Medical will complete an IPO, satisfy Nasdaq or other exchange requirements, or obtain listing approval.
- The SBC Medical warrant is exercisable only after a qualifying U.S. IPO, SPAC transaction, or other defined fundamental transaction and has a ten-year exercise window from that transaction date. It also contains a 9.99% equity blocker.
- HeartCore stated that it will not provide legal or accounting services, act as an investment adviser or broker-dealer, negotiate securities sales, participate in investor discussions, conduct due diligence, or provide investment valuation advice.
- The filing does not state the accounting treatment, timing of revenue recognition, collectibility, or fair value assigned to the cash fees or warrants.
- The press-release disclosure under Item 7.01 is furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Important Facts for Investors to Verify
- Whether SBC Medical made the $400,000 initial payment and whether the remaining $500,000 payments will be received on schedule.
- Whether SBC Medical ultimately completes a qualifying U.S. listing or other transaction, which is required before the warrant can be exercised.
- Whether SYLA completes its listing and satisfies the condition for the $150,000 payment.
- The final number of shares underlying the SYLA and SBC Medical warrants after applicable fully diluted share counts and adjustments.
- How HeartCore accounts for the consulting revenue, contingent payments, and warrant interests in subsequent financial statements.
- Any resulting dilution, valuation impact, concentration of customer or counterparty exposure, and effects on cash liquidity.